Quality of Life Effects of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa in People with Parkinson’s (P9-3.003)
Leonard Verhagen Metman(Northwestern University), Jason Aldred(Inland Northwest Health Services), Megha Shah(Emory University), Jaclyn Homola(AbbVie (United States)), Lars Bergmann(Universitätsklinikum Knappschaftskrankenhaus Bochum), Okeanis Vaou(The University of Texas at San Antonio Health Science Center), Thomas Kimber(Royal Adelaide Hospital), Jia Jia(Hubei University of Medicine), Rajesh Pahwa(University of Kansas Medical Center)
Cited by 0
Related Papers
Prevalence of and Factors Associated With Nurse Burnout in the US
|JAMA Network Open|2021|661
Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
|The American Journal of Human Genetics|2003|537
Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease
|Movement Disorders|2009|535
High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
|Annals of Neurology|1997|484
Randomized trial of deep brain stimulation for Parkinson disease
|Neurology|2012|448